vs
INTEGRA LIFESCIENCES HOLDINGS CORP（IART）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是INTEGRA LIFESCIENCES HOLDINGS CORP的1.6倍（$708.5M vs $434.9M），Medpace Holdings, Inc.同比增速更快（32.0% vs -1.7%），Medpace Holdings, Inc.自由现金流更多（$188.1M vs $-5.4M），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 8.6%）
英格拉生命科学控股是一家总部位于美国新泽西州普林斯顿的全球医疗器械企业，创立于1989年，主营皮肤再生、神经外科、重建外科与普通外科相关医疗器械。该公司开发的人工真皮是全球首款可规模化量产、用于治疗重度烧伤及其他皮肤创伤的人工皮肤组织。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
IART vs MEDP — 直观对比
营收规模更大
MEDP
是对方的1.6倍
$434.9M
营收增速更快
MEDP
高出33.8%
-1.7%
自由现金流更多
MEDP
多$193.5M
$-5.4M
两年增速更快
MEDP
近两年复合增速
8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $434.9M | $708.5M |
| 净利润 | — | $135.1M |
| 毛利率 | 50.8% | — |
| 营业利润率 | 5.3% | 21.6% |
| 净利率 | — | 19.1% |
| 营收同比 | -1.7% | 32.0% |
| 净利润同比 | — | 15.5% |
| 每股收益（稀释后） | $-0.03 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IARTMEDP
| Q4 25 | $434.9M | $708.5M | ||
| Q3 25 | $402.1M | $659.9M | ||
| Q2 25 | $415.6M | $603.3M | ||
| Q1 25 | $382.7M | $558.6M | ||
| Q4 24 | $442.6M | $536.6M | ||
| Q3 24 | $380.8M | $533.3M | ||
| Q2 24 | $418.2M | $528.1M | ||
| Q1 24 | $368.9M | $511.0M |
净利润IARTMEDP
| Q4 25 | — | $135.1M | ||
| Q3 25 | $-5.4M | $111.1M | ||
| Q2 25 | $-484.1M | $90.3M | ||
| Q1 25 | $-25.3M | $114.6M | ||
| Q4 24 | — | $117.0M | ||
| Q3 24 | $-10.7M | $96.4M | ||
| Q2 24 | $-12.4M | $88.4M | ||
| Q1 24 | $-3.3M | $102.6M |
毛利率IARTMEDP
| Q4 25 | 50.8% | — | ||
| Q3 25 | 51.5% | — | ||
| Q2 25 | 50.4% | — | ||
| Q1 25 | 50.8% | — | ||
| Q4 24 | 56.3% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | 54.0% | — | ||
| Q1 24 | 56.1% | — |
营业利润率IARTMEDP
| Q4 25 | 5.3% | 21.6% | ||
| Q3 25 | 2.9% | 21.5% | ||
| Q2 25 | -123.4% | 20.9% | ||
| Q1 25 | -4.0% | 20.3% | ||
| Q4 24 | 8.0% | 23.4% | ||
| Q3 24 | -2.1% | 21.1% | ||
| Q2 24 | -0.7% | 19.9% | ||
| Q1 24 | 1.1% | 20.4% |
净利率IARTMEDP
| Q4 25 | — | 19.1% | ||
| Q3 25 | -1.3% | 16.8% | ||
| Q2 25 | -116.5% | 15.0% | ||
| Q1 25 | -6.6% | 20.5% | ||
| Q4 24 | — | 21.8% | ||
| Q3 24 | -2.8% | 18.1% | ||
| Q2 24 | -3.0% | 16.7% | ||
| Q1 24 | -0.9% | 20.1% |
每股收益（稀释后）IARTMEDP
| Q4 25 | $-0.03 | $4.65 | ||
| Q3 25 | $-0.07 | $3.86 | ||
| Q2 25 | $-6.31 | $3.10 | ||
| Q1 25 | $-0.33 | $3.67 | ||
| Q4 24 | $0.25 | $3.67 | ||
| Q3 24 | $-0.14 | $3.01 | ||
| Q2 24 | $-0.16 | $2.75 | ||
| Q1 24 | $-0.04 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $263.7M | $497.0M |
| 总债务越低越好 | $726.6M | — |
| 股东权益账面价值 | $1.0B | $459.1M |
| 总资产 | $3.6B | $2.0B |
| 负债/权益比越低杠杆越低 | 0.70× | — |
8季度趋势，按日历期对齐
现金及短期投资IARTMEDP
| Q4 25 | $263.7M | $497.0M | ||
| Q3 25 | $267.9M | $285.4M | ||
| Q2 25 | $253.6M | $46.3M | ||
| Q1 25 | $273.3M | $441.4M | ||
| Q4 24 | $273.6M | $669.4M | ||
| Q3 24 | $277.6M | $656.9M | ||
| Q2 24 | $296.9M | $510.9M | ||
| Q1 24 | $663.1M | $407.0M |
总债务IARTMEDP
| Q4 25 | $726.6M | — | ||
| Q3 25 | $736.3M | — | ||
| Q2 25 | $745.9M | — | ||
| Q1 25 | $755.6M | — | ||
| Q4 24 | $760.5M | — | ||
| Q3 24 | $765.3M | — | ||
| Q2 24 | $770.2M | — | ||
| Q1 24 | $775.0M | — |
股东权益IARTMEDP
| Q4 25 | $1.0B | $459.1M | ||
| Q3 25 | $1.0B | $293.6M | ||
| Q2 25 | $1.0B | $172.4M | ||
| Q1 25 | $1.5B | $593.6M | ||
| Q4 24 | $1.5B | $825.5M | ||
| Q3 24 | $1.5B | $881.4M | ||
| Q2 24 | $1.5B | $763.6M | ||
| Q1 24 | $1.6B | $671.5M |
总资产IARTMEDP
| Q4 25 | $3.6B | $2.0B | ||
| Q3 25 | $3.6B | $1.8B | ||
| Q2 25 | $3.7B | $1.6B | ||
| Q1 25 | $4.1B | $1.9B | ||
| Q4 24 | $4.0B | $2.1B | ||
| Q3 24 | $4.1B | $2.1B | ||
| Q2 24 | $4.1B | $1.9B | ||
| Q1 24 | $4.1B | $1.8B |
负债/权益比IARTMEDP
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.8M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $-5.4M | $188.1M |
| 自由现金流率自由现金流/营收 | -1.2% | 26.6% |
| 资本支出强度资本支出/营收 | 4.0% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 1.43× |
| 过去12个月自由现金流最近4个季度 | $-31.1M | $681.9M |
8季度趋势，按日历期对齐
经营现金流IARTMEDP
| Q4 25 | $11.8M | $192.7M | ||
| Q3 25 | $40.9M | $246.2M | ||
| Q2 25 | $8.9M | $148.5M | ||
| Q1 25 | $-11.3M | $125.8M | ||
| Q4 24 | $50.7M | $190.7M | ||
| Q3 24 | $22.5M | $149.1M | ||
| Q2 24 | $40.4M | $116.4M | ||
| Q1 24 | $15.8M | $152.7M |
自由现金流IARTMEDP
| Q4 25 | $-5.4M | $188.1M | ||
| Q3 25 | $25.8M | $235.5M | ||
| Q2 25 | $-11.2M | $142.4M | ||
| Q1 25 | $-40.2M | $115.8M | ||
| Q4 24 | $21.1M | $183.0M | ||
| Q3 24 | $-7.2M | $138.5M | ||
| Q2 24 | $10.7M | $103.5M | ||
| Q1 24 | $291.0K | $147.2M |
自由现金流率IARTMEDP
| Q4 25 | -1.2% | 26.6% | ||
| Q3 25 | 6.4% | 35.7% | ||
| Q2 25 | -2.7% | 23.6% | ||
| Q1 25 | -10.5% | 20.7% | ||
| Q4 24 | 4.8% | 34.1% | ||
| Q3 24 | -1.9% | 26.0% | ||
| Q2 24 | 2.6% | 19.6% | ||
| Q1 24 | 0.1% | 28.8% |
资本支出强度IARTMEDP
| Q4 25 | 4.0% | 0.6% | ||
| Q3 25 | 3.8% | 1.6% | ||
| Q2 25 | 4.8% | 1.0% | ||
| Q1 25 | 7.6% | 1.8% | ||
| Q4 24 | 6.7% | 1.4% | ||
| Q3 24 | 7.8% | 2.0% | ||
| Q2 24 | 7.1% | 2.4% | ||
| Q1 24 | 4.2% | 1.1% |
现金转化率IARTMEDP
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
